Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Hits New 52-Week High

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has a listed Average True Range of 0.33 but today the low for CNAT has been $5.65 with a high of $6.43 – for a trading range of 0.78. Volumes have also increased significantly for the San Diego, CA-based biotech firm. CNAT’s average daily volume is 505,000 shares traded. Today, before noon, over 3.1 million shares have traded hands. However, the last share price for CNAT has barely moved since yesterday – up $0.09 for a gain of about 1.5%.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is a biotechnology company that develops and commercializes treatments for liver diseases. Emricasan is an orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. To date, emricasan has been administered to over 650 subjects in eight Phase 1 and eight Phase 2 clinical trials, and has been generally well-tolerated in both healthy volunteers and patients with liver disease. Emricasan has also been extensively profiled in in vitro tests and studied in many preclinical models of human disease.

Interestingly, today’s price action, while resulting in little gain, has resulted in touching upon a new 52-week high of $6.43. CNAT’s previous 52-week high was $6.30. Institutions own over 28% of CNAT stock and have added to that position to the tune of over 4% recently. YTD CNAT shares are up over 12%, and up over 175% for the past year. This performance is a little surprising given that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) missed on analyst estimates for Q4 EPS and revenues. Regardless, that seems to not have changed the minds of the analysts. All six that follow Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) rate CNAT shares as a “Strong Buy” with a consensus price target of $13.50.

3/31/2017
Ticker Symbol CNAT
Last Price a/o 12:01 PM EST  $                      6.02
Average Volume                    505,000
Market Cap (mlns)  $                  154.32
Sales (mlns) $0.80
Shares Outstanding (mlns) 26.07
Share Float (mlns) 25.3
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 3.60%
Short Interest Ratio 1.8
Quarterly Return 12.12%
YTD Return 12.33%
Year Return 176.64%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

Jaguar Animal Health Inc. (NASDAQ:JAGX) Formal Merger Agreement Pops Shares

Jaguar Animal Health Inc. (NASDAQ:JAGX)

Jaguar Animal Health Inc. (NASDAQ:JAGX) has formally entered into a merger agreement with Napo Pharmaceuticals, Inc. The deal was first announced on March 8,2017 when JGX shares closed trading at $0.68. The following day JAGX shares gapped up to open at $10.3 and hit a high of $1.23 before closing back at $1.03. Today JAGX shares gapped up again to open at $1.25 and have hit an inter-day high of $1.30 but are now trading around $1.10. Volumes are heavy – about 15 times their daily average.

Terms of the merger include a 3-to-1 Napo-to-Jaguar value ratio to calculate the relative ownership of the combined entity. As of January 31, 2017, Napo owned approximately 19% of Jaguar’s outstanding shares of common stock. Shareholders, option, and warrant holders of Jaguar Animal Health Inc. (NASDAQ:JAGX) , calculated on a fully diluted basis as of today (excluding approximately 365,437 shares issuable under securities convertible at $5.00 or more per share), will hold approximately 25% of the total outstanding fully diluted equity of Jaguar Animal Health Inc. (NASDAQ:JAGX). Conversely, the balance of the outstanding fully diluted equity of Jaguar will be held by existing Napo creditors, RSU, option and warrant holders together with new convertible debt and equity investors upon consummation of the merger. Holders of Napo common stock immediately prior to the merger (the “Napo Stockholders”) will receive contingent rights to receive, upon the satisfaction of certain conditions as described more fully below, up to 21.5% of Jaguar’s shares calculated on a fully-diluted basis.

Napo develops and commercializes gastrointestinal prescription products from plants used traditionally in rainforest areas. Jaguar Animal Health Inc. (NASDAQ:JAGX) develops and commercializes gastrointestinal products for companion animals, horses and production animals. Napo’s proprietary, patented gastrointestinal compound, crofelemer, is an anti-secretory agent sustainably harvested from the rainforest. The merger of the two companies will provide Jaguar with an important prescription revenue stream from sales of Mytesi™ (crofelemer 125mg delayed-release tablets), a Napo prescription product formerly known as Fulyzaq. Mytesi™ is a human drug approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

3/31/2017
Ticker Symbol JAGX
Last Price a/o 10:44 AM EST  $                      1.52
Average Volume                1,120,000
Market Cap (mlns)  $                    14.06
Sales (mlns) $0.10
Shares Outstanding (mlns) 14.8
Share Float (mlns) 9.28
Shortable Yes
Optionable No
Inside Ownership 0.00%
Short Float 15.24%
Short Interest Ratio 1.27
Quarterly Return 49.61%
YTD Return 32.68%
Year Return -39.87%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

Cinedigm Corp. (NASDAQ:CIDM) Expands Digital Market Footprint

Cinedigm Corp. (NASDAQ:CIDM)

Cinedigm Corp. (NASDAQ:CIDM) is one of the country’s leading distributors of media content. Cinedigm has distribution agreements with retail and digital storefronts such as WalMart, Target, iTunes, and Amazon. The company has a large library that holds over 52,000 films and TV episodes. Today the company announced that they will begin supporting Google’s Chromecast and Android TV platforms as well as Amazon Fire TV. The market responded to the news by sending CIDM shares up over 15% on heavy volume.

Initially the expansion will hit Google’s Chromecast – on April 21st. In June Amazon Fire will begin to receive the new service, followed by Android TV in July. Experts estimate that this expansion will add an additional 60 million devices to the available footprint for Cinedigm Corp. (NASDAQ:CIDM).

Despite its massive available footprint, Cinedigm Corp. (NASDAQ:CIDM) remains a nano-cap stock with around $15 million in market-cap on $94 million in sales. Its 52-week low is $0.90 and its 52-week high is $2.70. CIDM shares do not experience a lot of volatility. The Average True Range for CIDM shares is just $0.10. At the moment, CIDM shares are trading close to their cash/share value of $1.53.

Still, Cinedigm Corp. (NASDAQ:CIDM) is positioned well. The worldwide market it operates in is expected to grow to $65 billion from its current level of around $15 billion. Cinedigm had subscriber revenues of $only $300,000 in 2016 but expects that number to jump to $2 million for 2017. What is unknown is what it costs the company to acquire a new subscriber or retain an existing one. How they are able to execute their acquisition/retention strategy will be key to their future success.

3/31/2017
Ticker Symbol CIDM
Last Price a/o 10:13 AM EST  $                      1.52
Average Volume                    281,650
Market Cap (mlns)  $                    14.91
Sales (mlns) $94.00
Shares Outstanding (mlns) 10.96
Share Float (mlns) 8.31
Shortable Yes
Optionable No
Inside Ownership 19.10%
Short Float 7.04%
Short Interest Ratio 2.08
Quarterly Return -2.86%
YTD Return -5.56%
Year Return -35.24%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) Shares Rocket on FDA Fast Track Designation

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has received notice that the U.S, Food and Drug Administration (FDA) has granted the “Fast Track” designation to Coversin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare life-threatening disease of the blood. AKTX shares have skyrocketed on very heavy volumes and gapped up this morning to open at $9.20 from their close yesterday of $6.98. AKTX shares are normally thinly traded – their average daily volume figure is less than 16,500. However less than 15 minutes into trading over 1.5 million shares have traded hands.

Interestingly, Coversin is derived from a protein found in the saliva of the Ornithodoras moubata tick. Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) believes, and has clinical research to support, the notion that over 300 million years of evolution in this tick species has resulted in inhibitors that tightly bind, and target, highly conserved inflammatory mediators. The Coversin protein found in the ticks is required to be well tolerated by the parasite’s host in order to continue the tick’s feeding.

To date, Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has demonstrated: 1) full complement inhibition and marked lactate dehydrogenase reduction in a PNH patient with eculizumab resistance who is self-administering Coversin daily pursuant to an approved clinical protocol in the Netherlands, and who has now been administered Coversin since February 2016; 2) 100% inhibition of complement C5 activity by Coversin with once daily subcutaneous injections during our ongoing Phase 1b clinical trial in healthy volunteers; 3) that Coversin inhibits PNH red blood cell lysis in vitro; and 4) that complement inhibition is complete whether measured by ELISA CH50 U Eq/ml assay or sheep red blood cell lytic CH50 assay, as demonstrated in both a Phase 1b healthy volunteer study and a 28-day safety study in non-human primates.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares have not had a good time of it since they opened for trading on June 17, 2016. That day AKTX shares opened at $15.97. $15.97 also happens to be the high for this stock. Since then AKTX shares have hit a low of $6.22. The nano-cap biotech firm has but one analyst following its shares and they rate AKTX as a “sell”. The company has no sales and future sales are still down the road as the most developed drug candidate they are developing, Coversin, in just in a Phase 2 clinical study.

3/31/2017
Ticker Symbol AKTX
Last Price a/o 9:34 AM EST  $                      8.86
Average Volume                      16,500
Market Cap (mlns)  $                    81.57
Sales (mlns) $0.00
Shares Outstanding (mlns) 11.68
Share Float (mlns) 3.37
Shortable Yes
Optionable No
Inside Ownership 20.51%
Short Float 0.49%
Short Interest Ratio 1.02
Quarterly Return -2.19%
YTD Return -0.80%
Year Return 0.00%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Castle Brands Inc. (NYSEMKT:ROX) Hits New 52-Week High

Castle Brands Inc. (NYSEMKT:ROX)

Castle Brands Inc. (NYSEMKT:ROX) shares soared earlier this month on the company’s announcement that it had reached an agreement with WalMart (WMT) to supply Goslings Stormy Ginger Beer, and its diet offering, to all of its U.S, stores. Currently, Goslings Ginger Beer is the leading Ginger Beer in the USA. Yesterday Castle Brands announced that it had acquired an additional 20% stake in Gosling-Castle Partners Inc. – a strategic global export venture between Castle Brands Inc. and the Gosling family.

This development brings the ownership stake for Castle Brands Inc. (NYSEMKT:ROX) in the partnership to 80%. Castle brands concurrently announced the extension of an export and distribution agreement with Goslings that will now extend to 2030 with ten-year term extension options available.

Gosling’s Brothers Ltd. is the oldest company in Bermuda. Their product offerings include Black Seal Rum, Goslings Gold Rum, and Goslings Old Rum. Interestingly, Goslings also owns one of the few trademarked cocktails in the world – Goslings “Dark & Stormy”.

Castle Brands Inc. (NYSEMKT:ROX) shares are up over 97% YTD and up over 21% for the week. Sales have increased YoY since 2012 when the company posted a figure of $35.5 million. By 2016 that sales figure grew to $72.2 million. EPS has been lackluster as Castle Brands Inc. (NYSEMKT:ROX) has lost -$0.02 EPS for shareholders in each of the last two years. Also of moderate concern is the increase in the number of shares outstanding from 116.51 million in 2014 to 159.38 million in 2016.

ROX shares have a Relative Strength figure of over 80 which is considered to be in the low range of an “overbought” condition by experienced traders and investors. There has been talk of Castle Brands Inc. (NYSEMKT:ROX) due to its low multiples when compared against other beverage companies however the lack of profits has hurt the company in the eyes of analysts. But given that ROX shares just hit a new 52-week high, investors may not be in alignment with analyst recommendations.

3/31/2017
Ticker Symbol ROX
Last Price a/o 7:22 AM EST  $                      1.55
Average Volume                1,020,000
Market Cap (mlns)  $                  245.46
Sales (mlns) $74.70
Shares Outstanding (mlns) 163.64
Share Float (mlns) 85.57
Shortable Yes
Optionable No
Inside Ownership 1.80%
Short Float 1.65%
Short Interest Ratio 1.39
Quarterly Return 111.27%
YTD Return 97.37%
Year Return 59.56%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Eagle Bulk Shipping Inc (NASDAQ:EGLE) Says Dry Bulk Market Gained Momentum In Q4 2016

Eagle Bulk Shipping Inc (NASDAQ:EGLE)

Eagle Bulk Shipping Inc (NASDAQ:EGLE) released its financial report for the fourth quarter closed December 2016. Net loss cane at $142.4 million depending on a weighted average of over 48 million diluted shares unpaid. In the comparable quarter of FY2015, the company posted net loss of $79.7 million depending on a weighted average of almost 1.881 million diluted shares due. Earnings per share for Q4 2015 was retrospectively attuned to provide impact for the 1-for-20 reverse stock split.

The update

Net revenues in the quarter closed December 2016 came at $41.8 million versus $25.7 million recorded in the same quarter in FY2015. The jump in revenue can be attributed to an increased count of freight voyages, increased charter rates in Q4 2016, and increased available days following chartered in vessels.

Voyage costs for the quarter closed December 2016 came at $14.2 million against $10.3 million for the quarter closed December 2015. These costs have mainly increased due to a jump in bunker prices and a growing number of freight voyages.

Gary Vogel, the CEO of Eagle Bulk Shipping Inc (NASDAQ:EGLE), reported that the dry bulk industry gained momentum during fourth quarter, and they continue to witness promising indications through Q1 2017. Amid this encouraging trend, the company successfully raised increased growth capital late in Q4 2016 via the private placement, which together with the aggregate gross proceeds of $88 million generated in Q3 2016, supported acquisition of 11 modern best-quality Ultramax vessels since October 2016.

The company anticipates continuing to expand the fleet by using a renewal strategy that comprises selling six oldest vessels for proceeds of $24.8 million.

Eagle Bulk Shipping Inc (NASDAQ:EGLE) reported that they continued to make substantial progress during Q4 2016 in transforming company’s commercial business plan. This comprises an almost three-fold jump of business recorded on voyage terms as against Q4 2015, which offers enhanced margins and more effective fleet management.

The company even continued to develop chartered-in days to take advantage of opportunities available in the market. On the technical aspect, it continued to offer improved vessel operations, while the main focus on processes considerably reduced operating expenses during FY2016.

Eagle Bulk Shipping Inc (NASDAQ:EGLE) has a 50-day moving average of $5.59 and a 200-day moving average of 5.94. The 52-week low stands at 4.06 while EGLE has 52-week high of 23.60. EGLE shares price was up almost 4%, with a high of 5.83 during the day.

3/30/2017
Ticker Symbol EGLE
Last Price a/o 3:21 PM EST  $5.79
Average Volume 347.17K
Market Cap (mlns)  $ 275.02M
Shares Outstanding (mlns) 47.50M
Share Float (mlns) 43.12M
Inside Ownership 3.10%
Short Float 2.05%
Short Interest Ratio 2.55
Quarterly Return -3.02%
YTD Return -1.03%
Year Return -19.58%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

ParkerVision, Inc. (NASDAQ:PRKR) FY2016 Revenue Jumps Almost $4 Million

ParkerVision, Inc. (NASDAQ:PRKR)

ParkerVision, Inc. (NASDAQ:PRKR), a marketer and developer of semiconductor technology offerings for wireless applications, released its financial report for the quarter closed December 2016. Revenue surged by almost $4.1 million from FY2015 to FY2016, mainly as an outcome of patent licensing revenue.

The update

Jeffrey Parker, the CEO and Chairman of ParkerVision, Inc. (NASDAQ:PRKR), reported that they recorded progress with their global licensing plan in 2016 by making a settlement and obtaining a license deal with Samsung, a key milestone that underlines objective to obtain fair compensation for the application of their intellectual property. They continue to remain confident that they will get a resolution with other parties, and although they have suspended their probe at the ITC, they intend to move expeditiously on asking for a lift of the stopover in the corresponding district court case presently unresolved in the Middle District of Florida.

Parker added that the product development team has been committed in their measures to introduce a unique new Wi-Fi offering. Feedback obtained from prototype demonstrations so far has surpassed anticipations, and they look forward to commencing the marketing and sales campaign and delivering offering to clients in target markets in Q2 2017. They have invested in getting a new home Wi-Fi offering to market, and also in advancing Wi-Fi system-on-chip that permits them to take benefit of the investment they have made in their RF technologies. The management believes that they will witness strong positive feedback from target markets that will turn into revenue growth in FY2017 and beyond.

GAAP net loss for Q4 2016 came at $5.7 million against a net loss of $3.3 million for Q4 2015. The surge in net loss is mainly the outcome of a $1.8 million jump in projected fair value of the firm’s contingent payment obligation. ParkerVision, Inc. (NASDAQ:PRKR) reported that operating expenses for the fiscal year closed 2016 reflected a jump in litigation fees and costs of almost $3.6 million over the comparable year. The litigation fees and costs incurred in FY2016 have been compensated mainly from the funds obtained from BKI.

Cash used in operations came at almost $14.4 million in FY2016 which comprises almost $8.4 million for legal fees and costs compensated from BKI proceeds and almost $6 million for operating expenses excluding litigation.

Shares of ParkerVision, Inc. (NASDAQ:PRKR) started yesterday’s trading session at $1.99. The stock has a 52-week low of $1.60 while its 52-week high stands at $8.18. Its market cap stands around $29 million.

3/30/2017
Ticker Symbol PRKR
Last Price a/o 3:21 PM EST  $1.98
Average Volume 662.59K
Market Cap (mlns) $ 25.30M
Shares Outstanding (mlns) 12.78M
Share Float (mlns) 11.40M
Inside Ownership 4.90%
Short Float 21.63%
Short Interest Ratio 3.72
Quarterly Return -2.46%
YTD Return 7.61%
Year Return -36.74%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

What Is In Store For Argos Therapeutics Inc (NASDAQ:ARGS)?

Argos Therapeutics Inc (NASDAQ:ARGS)

Earlier in February Argos Therapeutics Inc (NASDAQ:ARGS) reported that its Phase III clinical study of ADAPT was unsuccessful. The study looked at utilizing Rocapuldencel-T in combination with sunitinib malate against sunitinib/other SOC therapies alone for the improvement in OS in subjects with metastatic Renal Cell Carcinoma.

The Independent Data Monitoring Committee determined the lack of efficacy with Roca-T, and concluded that no considerable benefit in patient survival was shown in the trial arm of this study.

The current scenario

Prior to the Phase III ADAPT study, Roca-T faced a phase II study with 21 patients which demonstrated promising enough results in OS benefit together with a tolerable safety profile to assure a Phase III trial exploring the advantage bringing Roca-T to standard of care treatments in advanced metastatic kidney cancer.

Some concerns related to this trial were the small sample size of subjects, lack of a side-by-side control group, along with the dismal performance in the deprived risk group which did not demonstrate an improved OS advantage relative to historical control norm statistics.

Argos Therapeutics Inc (NASDAQ:ARGS) management resolved most of these concerns in the Phase III study by taking more intermediate risk subjects, along with fewer risk elements, and kept dosing of Roca-T across disease progression in the study arm when subjects were switched from one treatment alternative to another.

With the latest report of Roca-T’s absence of a survival benefit in the larger ADAPT study, share price has declined by more than 75%.

The IDMC suggested it be stopped as a statistically notable survival benefit was not being demonstrated in the study arm relative to control. In their suggestion, they did not note a chance where such an advantage could be met if the study was enabled to continue until 100% of patient deaths happened in both arms.

Overall survival advantage of almost 6 months per significant OS curve separation in the study arm was the primary objective in the Argos Therapeutics Inc (NASDAQ:ARGS) ADAPT study. If the IDMC suggested stopping the study depending on failure to fulfill these criteria, it can happen that survival benefit, if any, can be less than 6 months.

The stock price of Argos Therapeutics Inc (NASDAQ:ARGS) has a value of $0.383 while the 52 week low stands at $0.31. The 52 week high, made on April 18, 2016, stands at $13.97.

3/30/2017
Ticker Symbol ARGS
Last Price a/o 3:21 PM EST  $0.38
Average Volume 677.45K
Market Cap (mlns) $ 23.55M
Shares Outstanding (mlns) 61.43M
Share Float (mlns) 21.48M
Inside Ownership 1.00%
Short Float 13.65%
Short Interest Ratio 4.33
Quarterly Return -92.10%
YTD Return -92.18%
Year Return -94.01%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

Uni-Pixel Inc (NASDAQ:UNXL) Q4 Revenue At $1.4 Million

Uni-Pixel Inc (NASDAQ:UNXL)

Uni-Pixel Inc (NASDAQ:UNXL) released their financial report for the fourth quarter closed December 2016. For Q4 2016, the revenue came at $1.4 million against revenue of $0.9 million for the quarter closed December 2015.

The update

Cost of revenues in Q4 2016 came at $4.6 million compared to $4.2 million for the quarter closed December 2015. It comprises certain non-cash charges, counting amortization, depreciation of equipment, stock-based compensation and other non-cash charges, which amounted $0.7 million during Q4 2016 compared to $1.2 million in the comparable period of FY2015. Excluding these non-cash expenses, adjusted cost of revenues came at $3.9 million in Q4 2016 against $3 million in Q4 2015.

Jeff Hawthorne, the CEO and President of Uni-Pixel Inc (NASDAQ:UNXL), reported that the company’s first year as a touchscreen component provider firm to the pioneer PC manufacturers was extremely fulfilling. Depending on the leading-edge phenomena of company’ technologies they were awarded several design wins, which they started bringing on in Q4 2016. They anticipate deliveries to gradually increase in 1H 2017, with shipments growing in the second half of this year. They are thrilled with the prospects ahead in 2017.

Hawthorne added that they remain focused on enhancing every aspect of their manufacturing capabilities as they increase manufacturing capacity to resolve the new design achievement volume production shipments.

Uni-Pixel Inc (NASDAQ:UNXL) reported that the majority of these design win plans are now moving from qualification to volume production. Each plan requires specific adjustments to meet XTouch sensors for the instruments in which they will get stylus and touchscreen capabilities. This customization procedure will, however, initially impact yields. Yields will increase as they move increase volume production.

Uni-Pixel Inc (NASDAQ:UNXL) stock is down almost 3% over the last quarter and down around 47% over the preceding six months. The equity has returned around 7% over the preceding year.

3/30/2017
Ticker Symbol UNXL
Last Price a/o 3:21 PM EST  $0.90
Average Volume 875.41K
Market Cap (mlns) $ 50.17M
Shares Outstanding (mlns) 55.75M
Share Float (mlns) 54.95M
Inside Ownership 1.40%
Short Float 9.51%
Short Interest Ratio 5.97
Quarterly Return -8.15%
YTD Return -8.43%
Year Return -2.17%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

Netlist, Inc. (NASDAQ:NLST) Improves Bottom Line Performance

Netlist, Inc. (NASDAQ:NLST)

Netlist, Inc. (NASDAQ:NLST) released their financial report for the year and fourth quarter closed December 2016. Revenue for 2016 came in at $19.7 million versus the revenue of $8 million for the same period, a year earlier. Gross profit for the fiscal year closed December 2016 stood at $7.4 million against gross profit of $2.1 million, for the fiscal year closed January 2016.

The stock saw unusually-high trading volume in previous trading session following a better than anticipated earnings announcement. Almost 1.273 million shares changed hands during trading, which is a jump of over 970% from the volume of 118,352 shares in previous session. The stock last closed at $1.00 with gains of over 7%.

The update

Netlist, Inc. (NASDAQ:NLST) reported that net loss for the year closed December 2016 came at ($11.2) million against a net loss of ($20.5) million in the comparable year period. This data comprise stock-based compensation cost of $1.5 million for the year closed December 2016 and $1.8 million for the period closed January 2016.

Revenues for the quarter closed December 2016 came at $5.5 million against revenue of $2.9 million for quarter closed January 2016. As of close of December 2016, cash/cash equivalents and restricted cash came at $12.6 million, working capital was $13 million, total assets were $20 million while stockholders’ deficit stood at ($0.5) million.

C.K. Hong, the CEO of Netlist, Inc. (NASDAQ:NLST), reported that they delivered strong financial performance in FY2016, supported by strong revenue growth. The more expanded revenue stems from a Joint Development Contract with Samsung which included Non-Recurring Engineering Fees to support the advancement of HybriDIMM, the play and plug storage class memory know-how, and innovative access to Samsung’s premium, memory offerings for resale.

During the year they took notable measures toward defending their valuable intellectual asset by initiating legal measures against SK hynix in the federal district court and at the ITC. Netlist is seeking, among other things, a prohibition on the importation of trespassing SK hynix server memory offerings and look forward to the prospect to present the case in the ITC at hearing in May.

Earlier in January, Netlist, Inc. (NASDAQ:NLST) reported the issuance of U.S. Patent pertaining to memory modules efficient of handshaking with a memory checker of a host system. This patent is linked to another U.S. Patent, which is one of 6 patents the company proclaimed last year against SK hynix LRDIMM and RDIMM enterprise memory offerings in the U.S. International Trade Commission and the U.S. District Court.

3/30/2017
Ticker Symbol NLST
Last Price a/o 3:21 PM EST $1.00
Average Volume 118.45K
Market Cap (mlns)  $ 61.11M
Shares Outstanding (mlns) 61.11M
Share Float (mlns) 55.31M
Inside Ownership 12.56%
Short Float 4.62%
Short Interest Ratio 21.56
Quarterly Return -0.99%
YTD Return -1.96%
Year Return -27.01%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.